CS/BSE/NSE/PR/2019-2020
May 23, 2019

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Stock Code: 530239

Dear Sir/Madam,

Sub: Press Release

With reference to above subject, please find enclosed Press Release of our company titled “Suven Life Sciences Ltd Announces the last patient last visit (LPLV) in their Phase 2 study of Masupirdine (SUVN-502) for Moderate Alzheimer’s Disease.”

This is for your information and record.

Thanking You,
Yours faithfully,
For Suven Life Sciences Limited

K. Hanumantha Rao
Company Secretary
News Release

Suven Life Sciences Ltd Announces the last patient last visit (LPLV) in their Phase 2 study of Masupirdine (SUVN-502) for Moderate Alzheimer’s Disease

Top-Line Phase 2 Data is on track to be presented at Alzheimer’s Association International Conference at Los Angeles on 17th July 2019

HYDERABAD, INDIA (May 23, 2019) Suven Life Sciences, a specialty biopharmaceutical company developing therapeutics in Central Nervous System diseases, today announced that the last patient has completed the last visit for its Phase 2 POC study of SUVN-502 for moderate Alzheimer’s disease.

The company expects to report the top-line data of this study at Alzheimer’s Association International Conference (AAIC) on 17th July 2019 at Los Angeles.

This randomized, double-blind, placebo-controlled study is evaluating the efficacy and safety of two doses of Masupirdine (SUVN-502) in moderate Alzheimer’s Disease patients who are taking both Aricept (donepezil) and Namenda (memantine). Study duration is 30 weeks. This is the first ever study to evaluate a triple combination therapy for moderate Alzheimer’s disease patients.

There is an urgent need for treatment options for patients with Alzheimer’s disease (AD) dementia since there are no new drugs discovered or developed since 2003.

We are very pleased to have completed last patient last visit (LPLV) and completing this trial represents a significant milestone for the development of our lead compound Masupirdine (SUVN-502) in this Phase 2 study in moderate Alzheimer’s disease and moves us a step closer to potentially bringing this new treatment option for people afflicted with moderate Alzheimer’s disease globally.

About Suven Life Sciences
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets. Suven has 4 clinical stage compounds, a Phase 2 finished Masupirdine (SUVN-502), Phase 2 ready SUVN-G3031, Phase 1 completed SUVN-D4010 and SUVN-911 and Phase 1 ready SUVN-I6107.

In addition to these clinical compounds the Company has nine (9) internally-discovered therapeutic drug candidates currently in various stages of pre-clinical development targeting conditions such as ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and pain.

For more information please visit our Web site at http://www.suven.com

Risk Statement:
Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.